BEAM — Beam Therapeutics Inc. stock price, charts and financials

QT54Beam Therapeutics Inc.

Beam Therapeutics Inc. (NASDAQ: BEAM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
27.29
-0.19-0.70%
OverviewShort InterestFilings
BEAMQT54Beam Therapeutics Inc.·NASDAQ
27.29-0.70%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
IOVA+0.63%$6.38KOD-4.98%$43.11TARS+2.81%$66.61CLDX+2.20%$42.63IRON+0.64%$77.93ATAI+0.07%$7.25GRAL+5.51%$73.31NRIX+0.55%$25.67
Snapshot
Index-P/E-EPS (ttm)-0.68Insider Own14.22%Shs Outstand102.88MPerf Week7.68%
Market Cap2.83BForward P/E-EPS next Y-4.66Insider Trans-3.38%Shs Float88.30MPerf Month-23.28%
Enterprise Value2.85BPEG-EPS next Q-Inst Own-Short Float26.29%Perf Quarter-12.68%
Income-84.25MP/S18.12EPS this Y-545.59%Inst Trans-Short Ratio10.24Perf Half Y11.12%
Sales156.04MP/B2.69EPS next Y-6.19%ROA-6.16%Short Interest23.22MPerf YTD-0.87%
Book/sh-P/C-EPS next 5Y-ROE-7.70%52W High37.99 -28.18%Perf Year50.16%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-28.62%52W Low15.49 76.15%Perf 3Y-2.73%
Dividend Est.-EV/EBITDA-Sales past 3/5Y31.91% -Gross Margin18.93%Volatility6.04% 5.72%Perf 5Y-70.13%
Dividend TTM-EV/Sales18.29EPS Y/Y TTM85.15%Oper. Margin-242.27%ATR (14)1.82Perf 10Y-
Dividend Ex-DateNov 04, 2013Quick Ratio14.57Sales Y/Y TTM156.25%Profit Margin-54.75%RSI (14)46.02Recom2.37
Dividend Gr. 3/5Y-Current Ratio14.57EPS Q/Q26.61%SMA200.78%Beta2.19Target Price54.75
Payout0.00%Debt/Eq0.23Sales Q/Q357.14%SMA50-10.04%Rel Volume0.60Prev Close27.48
Employees511LT Debt/Eq0.23EarningsNov 03SMA200-2.23%Avg Volume2.22MPrice27.29
IPO DateFeb 06, 2020Option/ShortYes / YesEPS/Sales Surpr.11.46% 189.13%Net Debt/EBITDA-0.46Volume1,324,046Change-0.70%
Analyst Ratings
DateActionAnalystRatingTarget
May-21-26ReiteratedH.C. WainwrightBuy$80
May-13-26ReiteratedTudor Pickering$40 → $39
Feb-25-26ReiteratedRBC CapitalSector Perform$26
Feb-20-26InitiatedCanaccordBuy$74
Jan-21-26ReiteratedTudor Pickering$37 → $41
Jan-07-26ReiteratedUBS$28
Nov-24-25InitiatedEvercore ISIOutperform$35
Oct-09-25InitiatedJefferiesBuy$41
May-07-25ReiteratedGuggenheimBuy$55
Mar-28-25UpgradeB of A SecuritiesNeutral → Buy
Latest News
Aug-05-26
Aug-05-2612:11PM
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focuszacks.com
Aug-04-26
Aug-04-2609:26AM
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimateszacks.com
07:14AM
Beam Therapeutics Q2 EPS $(1.18) Misses $(1.11) Estimate, Sales $490.000K Miss $16.370M EstimateBenzinga
07:00AM
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)globenewswire.com
Aug-03-26
Aug-03-2606:03AM
Beam Therapeutics: A Valuation With Upside Leftseekingalpha.com
Jul-23-26
Jul-23-2607:02AM
Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026Benzinga
07:00AM
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026globenewswire.com
02:15AM
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of “Moderate Buy” by Brokeragesdefenseworld.net
Jul-21-26
Jul-21-2603:14AM
Amova Asset Management Americas Inc. Has $91.16 Million Stock Holdings in Beam Therapeutics Inc. $BEAMdefenseworld.net
Jul-20-26
Jul-20-2601:30PM
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?fool.com
Jul-16-26
Jul-16-2607:30AM
The Battle For Sickle CellSeekingAlpha
Jul-09-26
Jul-09-2610:22AM
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investableseekingalpha.com
Jul-08-26
Jul-08-2601:29PM
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Casebenzinga.com
05:45AM
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeuticsfool.com
Jul-07-26
Jul-07-2606:22AM
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price TargetBenzinga
Company

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue16414064——————
Cost of Goods Sold Incl. D&A22922368——————
Gross Profit-64117-304——————
Selling, General and Administrative Excl. Other115114112——————
Research and Development416410368——————
Other Operating Expense-223-23-368——————
Operating Income-371-384-416——————
Interest Expense11440——————
Unusual Expense
—————————
Non-Operating Income (Expense)31734739——————
Net Income Before Taxes-65-80-377——————
Income Taxes
000——————
Consolidated Net Income-65-80-377——————
Net Income From Continuing Operations-65-80-377——————
Net Income-65-80-377——————
EPS (Recurring)-0.64-0.81-4.58——————
EPS (Basic, Before Extraordinaries)-0.64-0.81-4.58——————
EPS (Diluted)-0.68-0.81-4.58——————
EBITDA-32-30-355——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio17.1419.6031.78——————
Gross Margin-39.0283.57-475.00——————
Operating Margin-226.22-274.29-650.00——————
Net Margin-39.63-57.14-589.06——————
Shares Outstanding1039982——————
Market Capitalization2,8112,7442,034——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$41.23$34.05$26.88$19.70$12.52● Close Price0.00M2.95M5.90M8.85M11.80MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Simon AmyChief Medical OfficerJul 27 '26Sale25.7416,667429,03785,696Jul 29
Simon AmyChief Medical OfficerJun 30 '26Sale34.7337312,954102,363Jul 02
Evans John M.CEOJun 30 '26Option Exercise1.0325,00025,7501,072,205Jul 01
Evans John M.CEOJun 30 '26Sale34.3125,000857,6851,047,205Jul 01
Evans John M.CEOJun 29 '26Sale35.4925,000887,3521,047,205Jul 01
Evans John M.CEOJun 29 '26Option Exercise0.7625,00019,0311,065,868Jul 01
FMR LLC10 percent owner, other: See Remark 1Jun 26 '26Sale35.26251,4888,867,467854,583Jun 29
FMR LLC10 percent owner, other: See Remark 1Jun 25 '26Sale35.1233,3721,172,0251,106,071Jun 29
Ciaramella GiuseppePresidentJun 17 '26Option Exercise0.9635,50534,228253,911Jun 22
Evans John M.CEOApr 01 '26Sale24.5830,078739,3171,047,205Apr 06
Simon AmyChief Medical OfficerApr 01 '26Sale24.586,700164,686102,735Apr 06
Cavanagh Bethany JSVP, Finance and TreasurerApr 01 '26Sale24.583,24279,68851,171Apr 06
Bellon ChristineChief Legal OfficerApr 01 '26Sale24.585,956146,398109,711Apr 06
Ciaramella GiuseppePresidentApr 01 '26Sale24.5811,810290,290218,406Apr 06
Evans John M.CEOMar 31 '26Option Exercise0.6725,00016,7501,011,667Apr 01
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.